Abstract
Objective: This study examined productivity losses in European patients with newly diagnosed multiple myeloma (NDMM) undergoing autologous stem cell transplantation (ASCT), to better understand and model the impact of NDMM and lenalidomide maintenance therapy on productivity from a patient and societal perspective. Methods: A cross-sectional online patient survey was conducted across the UK, Germany, France, Spain and Italy. A partitioned survival model was used to estimate productivity loss and the impact of maintenance therapy, using human capital (HC) and friction cost approaches. Results: Of the 115 eligible survey respondents, 76.5% were economically active at the time of diagnosis and highlighted return to work as an important factor affecting their quality of life; only 39.1% of respondents were economically active post-ASCT. HC analyses estimated average total productivity losses per ASCT patient at EUR 290,601 over a 20-year period. Modelling the impact of maintenance therapy alone for these patients reduced average productivity losses by just over 10%. Conclusion: Patients with NDMM aspire to engage in productive lives post-ASCT, but most are unable to do so. Access to treatments extending remission and supporting engagement in a productive life can have a positive impact both for patients and wider society.
| Original language | English |
|---|---|
| Pages (from-to) | 393-401 |
| Number of pages | 9 |
| Journal | European Journal of Haematology |
| Volume | 103 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Oct 2019 |
Bibliographical note
Funding Information:The authors would like to thank Dr Marc Koopmanschap for kindly providing the country‐specific friction period data used in the FC model. The authors would also like to thank all patients and their caregivers for their willingness to take part in this important study. The authors acknowledge the contribution of Myeloma Patients Europe, Myeloma UK, Leukämiehilfe RHEIN‐MAIN eV, Arbeitsgemeinschaft Multiples Myelom, Plasmozytom (AMM‐Online), Associazione Italiana contro le leucemie‐linfomi e mieloma (AIL) and AIL Area Pazienti ONLUS for their input in the design and implementation of the study. The authors received editorial support provided by Rosie Morland, PhD, from Excerpta Medica, funded by Celgene Corporation. The authors had full access to the data and are fully responsible for content and editorial decisions for this manuscript.
Funding Information:
Funding information This study was funded by Celgene Corporation. The authors would like to thank Dr Marc Koopmanschap for kindly providing the country-specific friction period data used in the FC model. The authors would also like to thank all patients and their caregivers for their willingness to take part in this important study. The authors acknowledge the contribution of Myeloma Patients Europe, Myeloma UK, Leuk?miehilfe RHEIN-MAIN eV, Arbeitsgemeinschaft Multiples Myelom, Plasmozytom (AMM-Online), Associazione Italiana contro le leucemie-linfomi e mieloma (AIL) and AIL Area Pazienti ONLUS for their input in the design and implementation of the study. The authors received editorial support provided by Rosie Morland, PhD, from Excerpta Medica, funded by Celgene Corporation. The authors had full access to the data and are fully responsible for content and editorial decisions for this manuscript.
Publisher Copyright:
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Keywords
- autologous transplantation
- health services accessibility
- multiple myeloma
- return to work
- surveys and questionnaires